Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 945 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Delivery Type Clear all
Recruiting Phase 1 Interventional

SGLT2i, Pioglitazone, and Ketone Production in T2D

NCT07053319
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Empagliflozin 25 MG, Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 9:26 AM EDT
Recruiting Not applicable Interventional

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation

NCT06258993
View directory record Official record
Conditions
Breast Cancer
Interventions
Core Exercise Promotion Program, Affect-based exercise prescription, Effort-based exercise prescription
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 9:26 AM EDT
Completed Not applicable Interventional Results available

The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale

NCT06338592
View directory record Official record
Conditions
Lung Cancer, Lung Neoplasms/Diagnosis
Interventions
MyLungHealth, DecisionPrecision+
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
50 Years to 79 Years
Enrollment
31,303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 23, 2026, 9:26 AM EDT
Terminated Phase 3 Interventional Results available

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

NCT02660138
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 23, 2026, 9:26 AM EDT
Active, not recruiting Not applicable Interventional

Nested Pilot Study Comparing Two Treatments to Reduce Type 2 Diabetes Risk in At-Risk Delawareans

NCT07450118
View directory record Official record
Conditions
Prediabetes
Interventions
National Diabetes Prevention Program (DPP), Sleep Health Digital Application, Time-Restricted Eating (TRE)
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 9:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hyaluronidase Via LADD Scleroderma-induced Microstomia

NCT05995626
View directory record Official record
Conditions
Microstomia, Scleroderma
Interventions
Hyaluronidase, CO2 laser
Drug · Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 23, 2026, 9:26 AM EDT
Terminated Not applicable Interventional

Prime Time for Superficial Femoral Artery (SFA) - The SFA Study

NCT00902317
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Cryoplasty (PolarCath peripheral balloon catheter), Laser Angioplasty (Spectranetics), SilverHawk Atherectomy, Viabahn Endograft, Angioplasty/Stent (Guidant "Absolute" stent)
Procedure · Device
Lead sponsor
Arizona Heart Institute
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 15, 2009 · Synced Oct 23, 2026, 9:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multisite Observational Maternal and Infant Study for COVID-19

NCT05031468
View directory record Official record
Conditions
COVID-19
Interventions
Licensed or EUA SARS-CoV-2 vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 23, 2026, 9:26 AM EDT
Completed Not applicable Interventional

Model Predictive Control (MPC) Artificial Pancreas vs. Sensor Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) With Different Food Choices in the Outpatient Setting

NCT03767790
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
iAPS
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 23, 2026, 9:26 AM EDT
Completed Not applicable Interventional Results available

Omnipod Horizon™ Automated Glucose Control System Preschool Cohort

NCT04476472
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Omnipod Horizon™ Automated Glucose Control System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
2 Years to 5 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 23, 2026, 9:26 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy

NCT03830281
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Ultra-Rapid Lispro, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
32
States / cities
Concord, California • Fresno, California • Greenbrae, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 23, 2026, 9:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

NCT04713475
View directory record Official record
Conditions
GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
Interventions
PBGM01
Biological
Lead sponsor
Gemma Biotherapeutics
Industry
Eligibility
1 Month to 24 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Oakland, California • Minneapolis, Minnesota • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 9:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pilot Implementation Trial of Implementation Toolkits for Diabetes Coaching

NCT07766811
View directory record Official record
Conditions
Implementation Science, Type 1 Diabetes in Adolescence, Implementation Strategies
Interventions
Base Implementation Toolkit (BIT), BIT-Enhanced, BIT-Sustainment
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 9:26 AM EDT
Completed Phase 2 Interventional Results available

Therapy for Children With Advanced Stage Neuroblastoma

NCT01857934
View directory record Official record
Conditions
Neuroblastoma
Interventions
cyclophosphamide, topotecan, hu14.18K322A, peripheral blood stem cell harvest, surgical resection, cisplatin, etoposide, doxorubicin, vincristine, busulfan, melphalan, peripheral blood stem cell transplantation, natural killer cell infusion, radiation therapy, GM-CSF, G-CSF, mesna, levetiracetam, interleukin-2, Isotretinoin, CliniMACS
Drug · Biological · Procedure + 2 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 9:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis

NCT00749957
View directory record Official record
Conditions
Leber Congenital Amaurosis
Interventions
rAAV2-CB-hRPE65
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Worcester, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 23, 2026, 9:26 AM EDT
Terminated Not applicable Interventional Results available

Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes

NCT04090242
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
22 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
San Mateo, California • West Palm Beach, Florida • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 23, 2026, 9:26 AM EDT
Completed Not applicable Interventional Results available

Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy

NCT01714505
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs)
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 23, 2026, 9:26 AM EDT
Recruiting No phase listed Observational

Endometriosis Pain

NCT06101303
View directory record Official record
Conditions
Pelvic Pain, Endometriosis
Interventions
Psychophysical assessment, Psychophysical assessments of experimental pain, Blood, urine and saliva samples, Biopsy and surgery-related data.
Other · Behavioral · Diagnostic Test + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 23, 2026, 9:26 AM EDT
Recruiting Not applicable Interventional

The RESET System Pivotal Clinical Trial (Protocol Revision K)

NCT04101669
View directory record Official record
Conditions
Diabetes type2, Obesity
Interventions
RESET Liner, Sham
Device · Other
Lead sponsor
Morphic Medical Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
27
States / cities
Gilbert, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 9:26 AM EDT
Terminated Not applicable Interventional Results available

Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors

NCT01965002
View directory record Official record
Conditions
Soft Tissue Neoplasms
Interventions
MRgHIFU, Aspirin, Enoxaparin
Device · Drug
Lead sponsor
Pejman Ghanouni
Other
Eligibility
10 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 23, 2026, 9:26 AM EDT
Recruiting Not applicable Interventional

A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE

NCT05909046
View directory record Official record
Conditions
Pre-Gestational Diabetes, Type2diabetes, Pregnancy in Diabetic, Pregnancy, High Risk, Gestational Diabetes, Gestational Diabetes Mellitus in the Puerperium
Interventions
Immediate inpatient postpartum OGTT, Standard of care 4-12 week postpartum OGTT
Diagnostic Test
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 9:26 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 23, 2026, 9:26 AM EDT
Terminated Not applicable Interventional

Comparison of Tendon Transfer, Botox Injections and Ongoing Treatment in Hemiplegic Cerebral Palsy

NCT00250081
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Upper Extremity Tendon transfer, Botulinum Toxin injections in Upper Extremity, Regularly ongoing therapy
Procedure
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
4 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
10
States / cities
Sacramento, California • Wilmington, Delaware • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 23, 2026, 9:26 AM EDT
Completed Not applicable Interventional

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges

NCT03848767
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 23, 2026, 9:26 AM EDT